A personalized medicine approach to biologic treatment of rheumatoid arthritis: a preliminary treatment algorithm

Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis

(2011) M. H. Buch et al.   ANNALS OF THE RHEUMATIC DISEASES

Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries

(2011) K. Chatzidionysiou et al.   ANNALS OF THE RHEUMATIC DISEASES

B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: A six-month, national, multicenter, open-label study

(2011) Jérémie Sellam et al.   ARTHRITIS AND RHEUMATISM

Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up

(2011) Geertje M. Bartelds   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis: an exploratory study

(2011) R. Klaasen et al.   RHEUMATOLOGY

CCR5 blockade in rheumatoid arthritis: a randomised, double-blind, placebo-controlled clinical trial

(2010) A. W. R. van Kuijk et al.   ANNALS OF THE RHEUMATIC DISEASES

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

(2010) J. S. Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept

(2010) A. Jamnitski et al.   ANNALS OF THE RHEUMATIC DISEASES

Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial

(2010) P. P. Tak et al.   ANNALS OF THE RHEUMATIC DISEASES

Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients

(2010) Rogier M. Thurlings et al.   ARTHRITIS AND RHEUMATISM

Management of nonresponse to rituximab in rheumatoid arthritis: Predictors and outcome of re-treatment

(2010) E. M. Vital et al.   ARTHRITIS AND RHEUMATISM

Synovial tissue heterogeneity in rheumatoid arthritis in relation to disease activity and biomarkers in peripheral blood

(2010) Lisa G. M. van Baarsen et al.   ARTHRITIS AND RHEUMATISM

Body mass index and clinical response to infliximab in rheumatoid arthritis

(2010) Ruth Klaasen et al.   ARTHRITIS AND RHEUMATISM

Switching TNF-alpha antagonists in rheumatoid arthritis: The experience of the LORHEN registry

(2010) Roberto Caporali et al.   AUTOIMMUNITY REVIEWS

Efficacy and Safety of Retreatment in Patients with Rheumatoid Arthritis with Previous Inadequate Response to Tumor Necrosis Factor Inhibitors: Results from the SUNRISE Trial

(2010) P. J. MEASE et al.   JOURNAL OF RHEUMATOLOGY

Targeting B cells in immune-mediated inflammatory disease: A comprehensive review of mechanisms of action and identification of biomarkers

(2010) Thomas Dörner et al.   PHARMACOLOGY & THERAPEUTICS

The Gene Expression Profile in the Synovium as a Predictor of the Clinical Response to Infliximab Treatment in Rheumatoid Arthritis

(2010) Johan Lindberg et al.   PLoS One

Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register

(2010) W. Kievit et al.   RHEUMATOLOGY

Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study

(2009) G. M. Bartelds et al.   ANNALS OF THE RHEUMATIC DISEASES

The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: A prospective study

(2009) Ruth Klaasen et al.   ARTHRITIS AND RHEUMATISM

CD11c as a Transcriptional Biomarker to Predict Response to Anti-TNF Monotherapy With Adalimumab in Patients With Rheumatoid Arthritis

(2009) B Stuhlmüller et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Synovial Tissue Sublining CD68 Expression Is a Biomarker of Therapeutic Response in Rheumatoid Arthritis Clinical Trials: Consistency Across Centers

(2009) B. BRESNIHAN et al.   JOURNAL OF RHEUMATOLOGY

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

(2009) Josef S Smolen et al.   LANCET

Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritis

(2009) Valérie Badot et al.   ARTHRITIS RESEARCH & THERAPY

Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis

(2008) C Potter et al.   ANNALS OF THE RHEUMATIC DISEASES

Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation

(2008) Y K O Teng et al.   ANNALS OF THE RHEUMATIC DISEASES

Disease activity-guided rituximab therapy in rheumatoid arthritis: The effects of re-treatment in initial nonresponders versus initial responders

(2008) Rogier M. Thurlings et al.   ARTHRITIS AND RHEUMATISM

Synovial lymphoid neogenesis does not define a specific clinical rheumatoid arthritis phenotype

(2008) Rogier M. Thurlings et al.   ARTHRITIS AND RHEUMATISM

Analysis of apoptosis in peripheral blood and synovial tissue very early after initiation of infliximab treatment in rheumatoid arthritis patients

(2008) Carla A. Wijbrandts et al.   ARTHRITIS AND RHEUMATISM

Modulation of CCR2 in rheumatoid arthritis: A double‐blind, randomized, placebo‐controlled clinical trial

(2008) Clarissa E. Vergunst et al.   ARTHRITIS AND RHEUMATISM

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

(2008) Josef S Smolen et al.   LANCET

The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor   expression in the synovium

(2007) C A Wijbrandts et al.   ANNALS OF THE RHEUMATIC DISEASES